Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.64 USD | -3.54% | -5.34% | -50.63% |
May. 21 | JPMorgan Adjusts Teladoc Price Target to $16 From $19, Maintains Neutral Rating | MT |
Apr. 29 | Truist Securities Cuts Teladoc's Price Target to $15 From $17, Maintains Hold Rating | MT |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- The company appears to be poorly valued given its net asset value.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-50.63% | 1.8B | D+ | ||
+78.57% | 584M | - | - | |
+3.54% | 446M | - | ||
-74.51% | 113M | C- | ||
-28.06% | 91.45M | - | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- TDOC Stock
- Ratings Teladoc Health, Inc.